Silicon Investor - Geron Corp.

[Savant] Geron (Nasdaq: GERN) said members of management will present at three investor e...

Savant — 2/23/2026 6:34:38 PM

Geron (Nasdaq: GERN) said members of management will present at three investor events in early March 2026: TD Cowen (fireside chat) on March 2, 2026 in Boston, Barclays (fireside chat) on March 10, 2026 in Miami, and Leerink Partners in-person meetings on March 11, 2026 in Miami.

A live and archived audio webcast of each fireside chat will be available via the Investors & Media section of Geron’s website at www.geron.com.
Geron to present at March healthcare conferences | GERN Stock News

[Savant] Geron (GERN) to Release Quarterly Earnings on Wednesday Geron (GERN) to Release...

Savant — 2/18/2026 11:17:48 AM

Geron (GERN) to Release Quarterly Earnings on Wednesday

Geron (GERN) to Release Quarterly Earnings on Wednesday - Defense World

[Savant] Geron Amends Term Loan Facility to Extend Draw Deadlines Geron Amends Term Loan...

Savant — 1/6/2026 11:45:56 AM

Geron Amends Term Loan Facility to Extend Draw Deadlines

Geron Amends Term Loan Facility to Extend Draw Deadlines - TipRanks.com

[tktrimbath] My Semi-annual review of GERN GERN (market cap is $0.855B was $0.870B) ? Gero...

tktrimbath — 12/31/2025 4:34:53 PM

My Semi-annual review of GERN

GERN (market cap is $0.855B was $0.870B)

?

Geron (GERN) is a biotech that recently received FDA approval for their blood disorder treatment. Their product works on blood-related cancers, and may extend to other cancers.

?

Geron is a biotech, but seems a bit withered. I've held the stock since circa 1999. Then, they were leading edge, a major innovator, had grand plans for dramatically expanding human lifespans; and had a management team and philosophy that impressed me with their wisdom and insights into public reactions.

?

Delays inspired and required the sale of much of their intellectual property and divisions, which leaves them with the telomerase-related treatments. They may be more than good enough for the company to become impressively useful and profitable. Sadly, subsequent management teams seem to have lost the startup vigor, and the long term grand plan for revolutionizing medical care. Now, management seems like, well, managers, managers who are executing a plan but not a vision.

?

As I understand it, managing cell telomeres can manage to treat cell death by encouraging some cells to die (cancer) and discouraging others from dying prematurely (auto-immune diseases). Those two general applications cover a broad swath of medical issues, some of which have few or poor treatment options. Whether management recognizes the potential is highly uncertain.

?

DISCLOSURE LTBH since 1999 and continuing to hold, but do not plan on buying more unless I see significant positive changes at the company.

I continue to hold because selling so low has little benefit and I am an optimist.

(I've also collected links to the other discussion boards and my other stocks over on my blog. trimbathcreative.net

[Savant] SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, is investigat...

Savant — 7/18/2025 2:46:04 PM

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, is investigating potential violations of federal and state securities laws by certain officers and directors of Geron Corporation (NASDAQ: GERN), Viatris Inc. (NASDAQ: VTRS), Everus Construction Group, Inc. (NYSE: ECG), and SoundHound AI, Inc. (NASDAQ:SOUN). Shareholders who have held shares continuously since before certain dates may have standing to hold these companies harmless from the alleged harm caused by their officers and directors by making them personally responsible. You may also be able to assist in reforming each company’s corporate governance to prevent future wrongdoing.

Geron Corporation (NASDAQ: GERN)
If you have held Geron Corporation shares continuously since prior to February 28, 2024, you may have standing to hold Geron harmless from the alleged harm caused by the Company’s officers and directors by making them personally responsible. You may also be able to assist in reforming the Company’s corporate governance to prevent future wrongdoing. To learn more, visit: globenewswire.com, or contact Johnson Fistel, PLLP at jimb@johnsonfistel.com or (619) 814-4471.

Complaint Allegations
The previously filed Complaint alleges that Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Rytelo’s potential; notably, that the lack of awareness for Rytelo, the burden of the continued monitoring requirement, and the impacts of seasonality and existing competition resulted in an inability for Geron to capitalize on the purportedly significant unmet need for the drug, particularly among first-line patients and those outside the academic setting

Johnson Fistel, PLLP Investigates Claims on Behalf of

[Savant] The consensus price target of analysts on Wall Street is $4, which implies an in...

Savant — 7/11/2025 12:48:44 PM

The consensus price target of analysts on Wall Street is $4, which implies an increase of 65.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $4 respectively. As a result, GERN is trading at a discount of -189.86% off the target high and -189.86% off the low.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 5.60%. While earnings are projected to return 52.95% in 2025.

How Will Geron Corp (NASDAQ: GERN) Look After It Drops -266.67% From Its Highs? – Marketing Sentinel

[tktrimbath] My mid-year review of GERN INTRO Here's my semi-annual exercise to see if I rem...

tktrimbath — 6/30/2025 4:21:16 PM

My mid-year review of GERN

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.

Geron

GERN (market cap is $0.870B was $2.14B)

Geron, whose name is short enough that I don't have to use its symbol, is a leading-edge biotech that has a treatment for (pardon the copy and paste from their site) "low- to intermediate-1 risk myelodysplastic syndromes (MDS) in adults", aka certain blood cancers. They continue to develop treatments based on telomeres, the molecules which regulate chromosomal death, hence other cancers (and possibly auto-immune disorders?).

While Geron is considered leading-edge and is to be congratulated on their first FDA approval, their process has been long, which enables competition, and despite commercialization, has not become profitable. (2024 revenue of ~$77M but with expenses of ~$146M) Their financial situation looks much better than the previous decades of R&D, but the investing community has not been impressed. At least patients are finally being treated. Hopefully, the company becomes profitable, and the stock will reflect that.

I expected more. Geron's original goals were grander, basically being able to control many aspects of aging through telomeres, stem cells, and nuclear transfer, as I recall. They commissioned panels for actual wisdom and boldly embraced debate. I know they sold off some of the technologies (which is why I bought shares of LCTX) as a survival strategy. I get the impression that those first managers, founders, and officers have been replaced by lowered expectations. I expected a more aggressive introduction of their first product, more publicity for the success of an innovative technology, and a re-invigoration of that original mindset.

I see Geron from two perspectives. One: I shouldn't buy more if this is all there is after holding the stock since 1999/2000. Two: Finally, they may succeed thanks to the technology despite management.

I bought more after selling my house. I guess I'm a cautious optimist.

DISCLOSURE LTBH since 1999 and continuing to hold.

(I've also collected links to the other discussion boards and my other stocks over on my blog. trimbathcreative.net

& from my One Company One Story series on YouTube

youtu.be )

[Savant] ATLANTA, March 14, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit h...

Savant — 3/14/2025 11:16:44 AM

ATLANTA, March 14, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Geron Corporation (“Geron” or the “Company”) (NASDAQ: GERN). The lawsuit alleges that Defendants disseminated materially false and misleading statements and/or concealed material adverse facts concerning Rytelo’s (imetelstat) potential.

If you bought shares of Geron between June 7, 2024 and February 25, 2025, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights

globenewswire.com
===============================

Merck diversity leader to retire this summer; Geron seeks commercial chops for next CEO

pharmaceuticals.einnews.com

[tktrimbath] Imetelstat European approval From the company, "Geron is preparing to commerci...

tktrimbath — 3/11/2025 5:23:34 PM

Imetelstat European approval

From the company,
"Geron is preparing to commercialize RYTELO in select EU countries beginning in 2026, pending country-by-country reimbursement."

ir.geron.com

[Savant] GERN earnings call transcript fool.com

Savant — 2/26/2025 12:54:10 PM

[tktrimbath] My EOY Review of GERN INTRO Here's my semi-annual exercise to see if I remember...

tktrimbath — 12/31/2024 4:33:38 PM

My EOY Review of GERN

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.

Geron

GERN (market cap is $2.14B was $2.52B)

Geron (GERN) is an advanced biotech company that has recently (finally?) received FDA approval for their first treatment, a telomere-based technology for treating a type of blood cancer. They have other treatments in their pipeline, but my main interest is this first treatment because of the FDA approval. The approval enables GERN to more confidently advance other treatments, ideally in unmet areas with little competition.

My main concern is that I expected the approval to more immediately find use, acceptance, and subsequently revenues. Not yet. Is it just a matter of patience? One possibility is that the company has been in development mode for so long that they are having a slower or more difficult time transitioning to marketing, treatments, - and the revenues they need for sustainability. Another possibility may be a reliance on a buyout. For humanitarian reasons I hope all that is required is patience. For investment reasons I hope they advance the treatment and the company by remaining independent.

My experience with the first occurrence of Dendreon (DNDN, trimbathcreative.net dampens my enthusiasm. They had an FDA-approved cancer vaccine, were actively undermined, the bad guys were found guilty, but the shareholders lost their money, or at least I did. Hopefully, that won't happen this time.

DISCLOSURE LTBH since 1999 and continuing to hold. I bought more after selling my house.

(I've also collected links to the other discussion boards and my other stocks over on my blog. trimbathcreative.net

& from my One Company One Story series on YouTube

youtu.be )

[Savant] Geron’s stock has surged over 58% year-to-date following the success of its grou...

Savant — 12/30/2024 11:08:56 AM

Geron’s stock has surged over 58% year-to-date following the success of its groundbreaking product, RYTELO. Its potential for further success in Europe and as a life-changing treatment for myeloid hematologic malignancies makes it a hot pick for investors in the healthcare sector.

Geron (GERN) Stock Surges on Game-Changing New Treatment - TipRanks.com

[Savant] Needham & Company LLC reiterated their buy rating on shares of Geron ( NASDAQ:GE...

Savant — 12/23/2024 11:28:36 AM

Needham & Company LLC reiterated their buy rating on shares of Geron ( NASDAQ:GERN – Free Report) in a research note released on Friday morning, Benzinga reports. Needham & Company LLC currently has a $6.00 price objective on the biopharmaceutical company’s stock.

Several other research analysts have also commented on the company. Barclays upgraded Geron to a “strong-buy” rating in a research report on Friday, November 29th. HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Geron in a report on Tuesday, December 10th. Leerink Partners initiated coverage on shares of Geron in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target for the company. Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Scotiabank initiated coverage on shares of Geron in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.15.

Geron’s (GERN) Buy Rating Reiterated at Needham & Company LLC - Defense World

[tktrimbath] I'm surprised that the stock hasn't done better since FDA approval. Do any of o...

tktrimbath — 12/23/2024 11:16:24 AM

I'm surprised that the stock hasn't done better since FDA approval.
Do any of our small community have any idea why?

[tktrimbath] My mid-year review of GERN INTRO Here's my semi-annual exercise to see if I rem...

tktrimbath — 6/28/2024 8:19:13 PM

My mid-year review of GERN

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.

Geron

GERN (market cap is $2.52B was $1.15B)

Geron (GERN) has been working on highly innovative biotech for decades. Decades! Finally, the FDA has officially approved Geron's blood cancer treatment. They will probably start trying to treat other types of cancer, too. One estimate is that the treatment will cost over $100,000 which is large compared to many drugs, but is meeting an unmet need, and it may be a lower overall cost. One bit of specifity is that patients may now experience "24 weeks of freedom from the burden of red blood cell transfusions". (https://trimbathcreative.net/2024/06/07/geron-approved/)

Years, decades ago, Geron had a diversified portfolio of innovative and somewhat controversial treatments that could fight cancer by convincing certain cells to die, and fight auto-immune disorders by allowing certain cells to live. From that broad range of possibilities they've narrowed down to blood cancer.

The good news for stockholders is that within the previous six months the stock has risen from ~$2 to ~$5. Such news can generate greater premiums, but dilution has so reduced the value of the shares that the premuim may already be built in.

If the treatment can be applied to other ailments, then a multiplier may be appropriate, but the investing market may wait to see if the medical industry accepts and encourages its use.

This is also the era of hyperbolic claims of price appreciation. If there is irrational exuberance, I may sell at least some shares.

My experience with the first occurrence of Dendreon (DNDN, trimbathcreative.net dampens my enthusiasm. They had an FDA-approved cancer vaccine, were actively undermined, the bad guys were found guilty, but the shareholders lost their money, or at least I did. Hopefully, that won't happen this time.

DISCLOSURE LTBH since 1999 and continuing to hold. I bought more after selling my house. I could buy more, but I expect I'll wait until I hear about Geron's plans for expansion.

(Other commentary and stocks at: trimbathcreative.net
& from my One Company One Story series on YouTube youtu.be )

[tktrimbath] From my oldest blog, which tends to be about personal finance (but no one is pay...

tktrimbath — 6/7/2024 6:12:09 PM

From my oldest blog, which tends to be about personal finance (but no one is paying me so it wanders), my impressions from today's news. (June 7, 2024)
trimbathcreative.net

[tktrimbath] Geron gets approval. From BusinessWire; "Geron Announces FDA Approval of RYTELO...

tktrimbath — 6/7/2024 11:11:09 AM

Geron gets approval.

From BusinessWire;
"Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia"
businesswire.com

[tktrimbath] Sold my house. Bought a more affordable one. Bought a bit of: $GERN (The longer...

tktrimbath — 5/21/2024 11:17:47 AM

Sold my house. Bought a more affordable one.

Bought a bit of:
$GERN
(The longer story is at https://trimbathcreative.net/2024/05/17/time-to-buy-but-what/)

[cycleupcycledown] Yes sir….Im on it, not sure how I’m going to play it….IF she does a quick spike,...

cycleupcycledown — 4/14/2024 11:19:54 PM

Yes sir….Im on it, not sure how I’m going to play it….IF she does a quick spike, don’t know if I’ll cash, or hold “old turkey” for months

[tktrimbath] Warning: I rarely get biotech nomenclature right, except by chance but, An Advis...

tktrimbath — 3/15/2024 11:19:58 PM

Warning: I rarely get biotech nomenclature right, except by chance but,
An Advisory Panel is advising the FDA to approve (circa June/July 2024) - I think.

[cycleupcycledown] Article today said Imetelstat reached primary endpoint in phase 3 imerge trial. ...

cycleupcycledown — 3/15/2024 9:54:14 PM

Article today said Imetelstat reached primary endpoint in phase 3 imerge trial. Is that new news? I haven’t been keeping up….never mind, looked it up, old news

[tktrimbath] I think one or two voted against based on safety concerns. I think that was rele...

tktrimbath — 3/15/2024 9:39:28 PM

I think one or two voted against based on safety concerns.
I think that was released (leaked?) early which may explain the dip.

[Savant] wonder why 2 of the panelists voted against....conflict of interest?? PS...how ...

Savant — 3/15/2024 5:33:50 PM

wonder why 2 of the panelists voted against....conflict of interest??

PS...how interesting that the pps took a plunge coupla days ahead of the vote....have seen that before of other cos...

PPS...not a done deal yet, though could go well

[cycleupcycledown] Outside chance becomes a meme stock, efficacy on many fronts…..cracked the telom...

cycleupcycledown — 3/15/2024 3:45:38 PM

Outside chance becomes a meme stock, efficacy on many fronts…..cracked the telomeres code.

[tktrimbath] Yay. Whew. Good news. "The panel, by a wide 12-to-2 margin, voted in favor of t...

tktrimbath — 3/14/2024 7:25:08 PM

Yay. Whew. Good news.

"The panel, by a wide 12-to-2 margin, voted in favor of the benefits of the injectable drug, called imetelstat, stating the associated risks and toxicities of the treatment appear to be manageable."

reuters.com

[tktrimbath] We/Geron/GERN almost had good news? statnews.com

tktrimbath — 3/13/2024 1:03:00 PM

[tktrimbath] my semi-annual exercise of GERN INTRO Here's my semi-annual exercise to see if ...

tktrimbath — 12/29/2023 5:00:26 PM

my semi-annual exercise of GERN

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.

Geron

GERN (market cap is $1.15B was $1.63B)

For decades I've been able to simply describe Geron because so little changed. Now, they've finally announced news "Geron announces FDA acceptance of New Drug Application for imetelstat for the treatment of transfusion-dependent anemia in patients with lower risk." Simple descriptions run into detailed progress reports that sound encouraging while also being hard to understand. Their web site says it better. "Our ambition is to change lives by changing the course of blood cancer." And, "We’re committed to bringing the potential power of telomerase inhibition to patients with imetelstat." That's clearer. Let's see if my amateur understanding suffices to describe the situation.

Years, decades ago, Geron had a diversified portfolio of innovative and somewhat controversial treatments that could fight cancer by convincing certain cells to die, and fighting auto-immune disorders to allow certain cells to live. From that broad range of possibilities they've narrowed down to blood cancer.

The good news is in that first paragraph, "Geron announces FDA acceptance of New Drug Application..." That sort of news could apply a premium to a stock price. I looked forward to it. It hasn't happened. There are several possibilities for why it didn't.

The premium is already included.

No one knows, or no longer cares about news from Geron. I've held the stock for over two decades. Few folks have that patience.

News in the industry may lower confidence.

Dilution has so reduced the value of the shares that the premuim is built in, but share price doesn't show it because there are so many shares in the market.

People want more proof of the technology, or the market.

The product may be considered too expensive (ala DNDN from ten years ago.)

Competition may have caught up to them.

I don't know. My style of investing involves some research, but nothing detailed until it matters. As I am a LTBH shareholder, I do not plan to trade the stock; so, there's less urgency for me to track the details. My curiosity may inspire to bring my understanding up to date.

New medical treatments have the potential to be used for more than one ailment. Geron's trails are targeted at blood cancer, but if it proves successful the company can expand and the stock price can reflect the multiplier effect.

Speculation is easy, but also moot. The FDA is the power, and they've accepted the New Drug Application. It is possible that a long wait may be over.

And...

(Mostly a copy&paste for my biotech investments with the names changed)

One hurdle with biotechs is making sure the treatment is reliable, effective, safe, and commercially viable. Another hurdle with innovative treatments is gaining FDA approval is a reasonable time. Treatments for unmet needs have pressure for early approval. Innovative treatments have pressures encouraging the FDA to be cautious. We may soon see how the technical, political, medical, and societal pressures affect Geron's treatment and Geron's viability and GERN's performance.

DISCLOSURE LTBH since 1999 and continuing to hold. I bought more when they mentioned specific years for clinical trials and approval goals.

(I've also collected links to the other discussion boards and my other stocks over on my blog. trimbathcreative.net

& from my One Company One Story series on YouTube

youtu.be )

[tktrimbath] Bleeding? Yeah, but I'm emotionally bled dry. Somehow hope remains. Applying fo...

tktrimbath — 6/30/2023 8:02:29 PM

Bleeding? Yeah, but I'm emotionally bled dry.
Somehow hope remains. Applying for FDA approval helps. Dilution hurts.

[Savant] T, more like bleeding wallet for long term holders.... have a small position fro...

Savant — 6/30/2023 7:43:51 PM

T, more like bleeding wallet for long term holders.... have a small position from original
They had hi hopes in beginning....then the govt/other attacks on stem cell research started..

[tktrimbath] INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I...

tktrimbath — 6/30/2023 7:25:24 PM

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.

Geron

GERN (market cap is $1.63B was $0.922B)

Geron is a leading-edge (some say bleeding-edge, but that sounds too graphic) biotech firm that is applying their knowledge of telomere management for treatments like hematological disorders. My understanding is that they plan to apply (or did they already?) for FDA approval within the next 6-9 months, with commercialization happening shortly after that.

Geron started decades ago with much broader, yet even more ambitious goals. Geron takes its name from gerontology, a field that the company saw as a large unmet need, as in, everyone who wants to live a longer life. They were developing technologies that are attractive to the immortality set. Now, their scope and depth are smaller. They've sold off most of their intellectual property to remain in business (disclosure: I also hold stock in Lineage Cell Therapeutics - LCTX, to invest in one of those technologies), which has also resulted in significant stock dilution.

I believe many have been ignoring GERN because it involves learning about telomeres (something manages cell death or cell life) and terms like hematological (blood-related). The company has not delivered the product despite decades of work, and there's that significant dilution.

If Geron receives FDA approval, they should get a lot of attention in the medical community, among patients, and GERN should get more positive interest from the investment community.

If, may, probably are the kinds of terms that have always been more speculative in Geron's work, but they may be on the cusp of less speculation and more real application.

IF Geron succeeds with this treatment, and IF the treatment can be extended to other ailments, then Geron, the patients, GERN, and the stockholders may benefit.

(Mostly a copy&paste for my biotech investments with the names changed)

One hurdle with biotechs is making sure the treatment is reliable, effective, safe, and commercially viable. Another hurdle with innovative treatments is gaining FDA approval is a reasonable time. Treatments for unmet needs have pressure for early approval. Innovative treatments have pressures encouraging the FDA to be cautious. We may soon see how the technical, political, medical, and societal pressures affect Geron's treatment and Geron's viability and GERN's performance.

DISCLOSURE LTBH since 1999 and continuing to hold. I bought more when they mentioned specific years for clinical trials and approval goals.

(I've also collected links to the other discussion boards and my other stocks over on my blog. trimbathcreative.net

& from my One Company One Story series on YouTube

youtu.be )

[tktrimbath] The Motley Fool had a favorable mention for GERN. I don't trust them as much as...

tktrimbath — 2/14/2023 11:46:58 PM

The Motley Fool had a favorable mention for GERN.
I don't trust them as much as I did when they were new, but good press is worth knowing about.
fool.com

[Savant] GERN up 64% premar, backed off some now seekingalpha.com

Savant — 1/4/2023 12:01:55 PM

[tktrimbath] INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I...

tktrimbath — 12/30/2022 4:57:38 PM

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.

Geron

GERN (market cap is $0.922B was $0.585B)

Geron is a leading-edge biotech aimed at treating blood disorders by using innovative telomerase techniques. Telomeres are the end caps to chromosome that regulate cell division and cell death. Too aggressive cell death can be associated with autoimmune diseases. Too aggressive cell division can be cancerous. Control cell division and cell death and it may be possible to treat more than their target disorder, thereby multiplying the treatments' and the company's impact.

The company has been working on developing a commercially viable treatment for over twenty years and may finally be within a year or two of applying for FDA approval. That's the good news.

(Mostly a copy&paste for my biotech investments with the names changed)

One hurdle with biotechs is making sure the treatment is reliable, effective, safe, and commercially viable. Another hurdle with innovative treatments is gaining FDA approval is a reasonable time. Treatments for unmet needs have pressure for early approval. Innovative treatments have pressures encouraging the FDA to be cautious. We may soon see how the technical, political, medical, and societal pressures affect Geron's treatment and Geron's viability and GERN's performance.

DISCLOSURE LTBH since 1999 and continuing to hold. I bought more when they mentioned specific years for clinical trials and approval goals.

(I've also collected links to the other discussion boards and my other stocks over on my blog. trimbathcreative.net

& from my One Company One Story series on YouTube

youtu.be )

[Savant] Major stock option grants to new hires GERN -1.9396% [graphic] Thu, October ...

Savant — 10/24/2022 10:04:47 AM

Major stock option grants to new hires

GERN
-1.9396%

Thu, October 20, 2022 at 3:30 PM

In this article:

GERN
-1.9396%

Recommendation Rating
Buy

FOSTER CITY, Calif., October 20, 2022--( BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 843,260 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

The stock options were granted on October 19, 2022 at an exercise price of $2.25 per share, which is equal to the closing price of Geron common stock on the date of grant. Stock options representing an aggregate of 710,000 shares have a 10-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment for the respective employees and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates. Stock options representing an aggregate of 133,260 shares have a 10-year term and vest in full upon achievement of certain regulatory milestones, subject to continued employment with Geron through the applicable vesting dates. All of the stock options were granted as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Geron’s 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.

[cycleupcycledown] I'm hoping for some sort of deal or good news before Jan results. In sum at $2.3...

cycleupcycledown — 10/8/2022 12:12:11 AM

I'm hoping for some sort of deal or good news before Jan results. In sum at $2.30 in trading acct.......recent dojis might precede a rally

[Savant] Geron Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Fr...

Savant — 8/26/2022 9:52:17 AM

Geron Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis

08/22/2022

Download this Press ReleasePDF Format (opens in new window)

- Preclinical data showed synergistic and additive effects of combination imetelstat and ruxolitinib
- Study intended to explore potential for disease modification with imetelstat in earlier, frontline myelofibrosis setting
- Single-agent imetelstat currently being studied in a separate Phase 3 trial designed to confirm clinically meaningful benefits observed in relapsed/refractory MF patients in Phase 2 study

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the first patient has been dosed in IMproveMF, a Phase 1 study evaluating imetelstat, a first-in-class telomerase inhibitor, in combination with ruxolitinib in patients with frontline myelofibrosis (MF).

“We designed the Phase 1 IMproveMF study based on preclinical data that showed the sequential treatment of ruxolitinib followed by imetelstat had a selective inhibitory effect on malignant MF stem cells, while sparing normal hematopoietic stem cells. This disease-modifying potential of imetelstat to affect the malignant clones driving disease progression differentiates it from any other drug currently approved or in development for myelofibrosis treatment,” said Faye Feller, MD, Executive Vice President, Chief Medical Officer of Geron. “Given these preclinical data, we want to explore the potential for disease modification with imetelstat in the earlier, frontline disease setting. In parallel, our separate IMpactMF Phase 3 trial is ongoing in MF patients who are relapsed/refractory to JAK inhibitors. This Phase 3 trial is designed to confirm the results from the IMbark Phase 2 study where single-agent imetelstat treatment resulted in multiple clinically meaningful benefits, including symptom response and potential improvement in overall survival.”

“Upon diagnosis, intermediate-2 and high-risk myelofibrosis patients typically receive ruxolitinib as the primary therapy, which reduces enlarged spleens and alleviates symptoms, but does not change the course of the disease. As a non-JAK inhibitor treatment option with a potentially novel mechanism of action, imetelstat could provide an additive benefit of disease modification when combined with ruxolitinib,” said John Mascarenhas, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and a principal investigator on the IMproveMF study. “The dosing of the first patient is an important step in identifying a potential safe and efficacious dose and schedule of imetelstat and ruxolitinib in frontline MF.”

IMproveMF is a single arm, open label, two-part Phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of imetelstat in combination with ruxolitinib as a frontline treatment in patients with Intermediate-2 or High-risk MF (frontline MF). In both parts, patients will receive ruxolitinib followed by imetelstat, a dosing schedule that showed synergistic and additive effects of the two drugs in preclinical experiments. Part 1 will enroll up to 20 frontline MF patients who, at the time of enrollment, have received an optimized dose of ruxolitinib, to which imetelstat treatment will be added at increasing dose levels based on safety and tolerability. The primary purpose of Part 1 is to identify a safe dose for treating frontline MF patients with a combination of imetelstat and ruxolitinib. If a safe dose is identified in Part 1, participants in Part 2 will be JAK inhibitor naïve and will receive treatment with ruxolitinib after screening and enrollment at a starting dose based on standard-of-care or local prescribing information. Treatment with single-agent ruxolitinib will continue for at least 12 weeks, including four consecutive weeks at a stable dose prior to the addition of imetelstat. Part 2 is designed to confirm the safety profile of imetelstat in combination with ruxolitinib and to evaluate for preliminary clinical activity of the combination. Geron expects to present preliminary results from this study by the end of 2023.

The study is enrolling patients and is being conducted at three trial sites in the U.S., two of which are currently open for patient screening. For more information, please visit ClinicalTrials.gov (Identifier NCT05371964).

About Imetelstat

Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic malignancies. Data from Phase 2 clinical trials provide strong evidence that imetelstat targets telomerase to inhibit the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies resulting in malignant cell apoptosis and potential disease-modifying activity. Imetelstat has been granted Fast Track designation by the United States Food and Drug Administration for both the treatment of patients with non-del(5q) lower risk MDS who are refractory or resistant to an erythropoiesis stimulating agent and for patients with Intermediate-2 or High-risk MF whose disease has relapsed after or is refractory to janus associated kinase (JAK) inhibitor treatment.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

[tktrimbath] PS That was a comment I made about ten years ago.

tktrimbath — 8/14/2022 2:05:37 AM

[tktrimbath] New blog post and short video from me about Geron. "I've owned their stock, GER...

tktrimbath — 8/12/2022 5:14:34 PM

New blog post and short video from me about Geron.

"I've owned their stock, GERN, since 1999, the only time I bought a stock based on a hot tip. Thirteen years later the concept of 'hot' is debatable."
trimbathcreative.net

[Savant] CC on 11th...

Savant — 8/4/2022 4:41:36 PM

[cycleupcycledown] Leak??.....m and a???......next meme?

cycleupcycledown — 8/4/2022 3:51:15 PM

[cycleupcycledown] That's one textbook flag, nice pole

cycleupcycledown — 7/19/2022 12:37:54 PM

[cycleupcycledown] Imetelstat has been given for many moons, surely some participants know what's u...

cycleupcycledown — 7/14/2022 4:57:42 PM

Imetelstat has been given for many moons, surely some participants know what's up.

[cycleupcycledown] Seasonally August is best month for GERN, been prepared in advance, I knew fact ...

cycleupcycledown — 7/5/2022 8:35:02 PM

Seasonally August is best month for GERN, been prepared in advance, I knew fact months ago.

[tktrimbath] My mid-year review of GERN INTRO Here's my semi-annual exercise to see if I rem...

tktrimbath — 6/30/2022 8:01:46 PM

My mid-year review of GERN

INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.

Geron

GERN (market cap is $0.585B was $0.393B)

Geron is a leading edge biotech firm that has been hanging on that edge for at least as long as I've owned the stock (since 1999). Their primary focus has been reduced to telomerase and blood disorder treatments, ala Imetelstat, after having sold off other divisions to raise funds to continue the work. Though long delayed and anticipated they have finally reached Phase 3 for at least one of the treatments. They expect results early 2023 after which they plan to submit the drug's application to the FDA. Commercialization could happen as early as 2024. That schedule is aided by Imetelstat's Fast Track and Orphan Drug statuses.

This journey has taken so long that it is hard to believe it is near. Is their leading edge blunted? That heritage may also partly explain why there doesn't seem to be a surge of interest. There is some renewed interest, but not what I expect from a biotech about to enter commercialization. Who knows more, the current shareholders or the reluctant ones?

DISCLOSURE LTBH since 1999 and continuing to hold. I bought more when they mentioned specific years for clinical trials and approval goals.

(I've also collected links to the other discussion boards and my other stocks over on my blog trimbathcreative.net )

[cycleupcycledown] Been buying the GERN dips with some side action, good mover....In at $1.25 yeste...

cycleupcycledown — 6/14/2022 10:27:43 PM

Been buying the GERN dips with some side action, good mover....In at $1.25 yesterday

[Savant] Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company fo...

Savant — 5/18/2022 9:28:44 AM

Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, plans to present a company overview at the H.C. Wainwright Global Investment Conference. The presentation will be available as an on-demand session beginning May 24, 2022 at 7 a.m. ET.

A webcast of the presentation will be available through the Investor Relations section of Geron's website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

[cycleupcycledown] Dats one beautiful cup and handle, one more leg up???

cycleupcycledown — 5/11/2022 1:52:55 AM

[cycleupcycledown] Cashed first " royalty " check, sold 1% of shares....99 more months to go..........

cycleupcycledown — 4/20/2022 2:00:01 AM

Cashed first " royalty " check, sold 1% of shares....99 more months to go.......( bought a bunch, gonna dollar cost average OUT".........autopilot

[cycleupcycledown] Hopefully, we get some efficacy news soon.

cycleupcycledown — 4/4/2022 2:25:38 PM

[Savant] Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical c...

Savant — 4/4/2022 9:53:17 AM

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 53,333,334 shares of its common stock and pre-funded warrants to purchase 18,095,238 shares of common stock, together with accompanying warrants to purchase 35,714,286 shares of common stock. The combined offering price to the public of each share of common stock and accompanying warrant was $1.05. The combined offering price to the public of each pre-funded warrant and accompanying warrant was $1.049. The common stock and pre-funded warrants were sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $1.45 per share and expires five years from the date of issuance; however, such term will be shortened upon achievement of a regulatory milestone.

The estimated net proceeds to Geron from this underwritten public offering are approximately $70 million, after deducting the underwriting discount and other estimated offering expenses payable by Geron. Geron currently intends to use the net proceeds from this public offering, together with its existing cash, cash equivalents, restricted cash and marketable securities, to fund potential regulatory filings in the United States and European Union for imetelstat in lower risk myelodysplastic syndromes (MDS), assuming top-line results in the IMerge Phase 3 clinical trial are supportive, and to support toward the completion of the IMpactMF clinical trial in refractory myelofibrosis and the planned exploratory studies in new indications, including IMproveMF and investigator-led trials in acute myeloid leukemia and higher risk MDS, the preclinical work in lymphoid malignancies and the discovery research program related to next generation telomerase inhibitors.

Stifel and Baird acted as joint book-running managers for the public offering and Needham & Company acted as lead manager.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock, pre-funded warrants and accompanying warrants described above was previously filed with the Securities and Exchange Commission (SEC) and subsequently declared effective by the SEC. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's web site at www.sec.gov. Copies of the final prospectus supplement relating to the offering may also be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at 415-364-2720 or by email at syndprospectus@stifel.com or Robert W. Baird & Co. Incorporated, Attention: Syndicate Department, 777 East Wisconsin Avenue, Milwaukee, Wisconsin 53202, by telephone at 800-792-2473 or by email at syndicate@rwbaird.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Use of Forward-Looking Statements

Investors are cautioned that statements in this press release regarding the anticipated net proceeds from this public offering and Geron's intended use of the net proceeds from this public offering constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks and uncertainties related to: higher than estimated offering expenses; market and other conditions; and the impact of general economic, industry or political conditions in the United States or internationally, including the impact of the COVID-19 pandemic and/or the Russia/Ukraine conflict on Geron's business operations and activities. Geron will continue to need significant additional capital to fund its operations and may be unable to raise capital when needed, which would force Geron to delay, reduce or eliminate its imetelstat development program. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on other potential factors that could affect Geron's results and other risks and uncertainties can be found under the heading "Risk Factors" in Geron's periodic reports, including its annual report on Form 10-K for the year ended December 31, 2021 and in the final prospectus supplement related to the public offering filed with the SEC on March 30, 2022, each available on the SEC's web site at www.sec.gov. Geron expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

View source version on businesswire.com: businesswire.com